Biktarvy vs Triumeq
Side-by-side cost comparison based on Medicare Part D data
Biktarvy
Bictegravir/Emtricitabine/TAF
Manufactured by Gilead
Triumeq
Dolutegravir/Abacavir/Lamivudine
Manufactured by ViiV Healthcare
Triumeq costs 4% less per claim than Biktarvy ($3,580.00 vs $3,746.00). A generic version of Triumeq is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Biktarvy | Triumeq |
|---|---|---|
| Avg Cost Per Claim | $3,746.00 | $3,580.00 |
| Total Medicare Spending | $3.8B | $1.9B |
| Total Beneficiaries | 85,000 | 44,000 |
| Total Claims | 1,020,000 | 524,000 |
| Annual Cost/Patient | $44,953.00 | $42,636.00 |
| Year-over-Year Change | +12.8% | -4.2% |
| Generic Available | No | Yes |
| Patent Expiration | Feb 7, 2033 | Jan 31, 2023 |
| Manufacturer | Gilead | ViiV Healthcare |
| Condition | HIV | HIV |
| Generic Name | Bictegravir/Emtricitabine/TAF | Dolutegravir/Abacavir/Lamivudine |
Biktarvy vs Triumeq: What the Data Shows
Biktarvy (Bictegravir/Emtricitabine/TAF) and Triumeq (Dolutegravir/Abacavir/Lamivudine) are both used to treat hiv. Based on Medicare Part D data, Triumeq costs $3,580.00 per claim, which is 4% less than Biktarvy at $3,746.00 per claim.
Medicare spent $3.8B on Biktarvy and $1.9B on Triumeq. In terms of patient reach, Biktarvy serves more beneficiaries (85,000 vs 44,000).
Year-over-year spending changed +12.8% for Biktarvy and -4.2% for Triumeq. Biktarvy saw significant spending growth, suggesting increased utilization or price increases.
Triumeq has a generic available, while Biktarvy remains brand-only until its patent expires Feb 7, 2033.
Frequently Asked Questions
Triumeq is cheaper at $3,580.00 per claim, compared to $3,746.00 for Biktarvy. That makes Triumeq about 4% less expensive per claim based on Medicare Part D data.
Yes, both Biktarvy and Triumeq are used to treat hiv. Your doctor can help determine which medication is more appropriate for your specific situation.
Triumeq has a generic version (Dolutegravir/Abacavir/Lamivudine) available, which is typically much cheaper. Biktarvy is currently brand-only, with patent expiring Feb 7, 2033.
Medicare Part D spent $3.8B on Biktarvy covering 85,000 beneficiaries, and $1.9B on Triumeq covering 44,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.